ライフサイエンスコーパス: gallium nitrate

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 diac allografts after immunosuppression with gallium nitrate.

2 to treatment with the anti-CD4 mAb GK 1.5 or gallium nitrate.

3 were accepted due to immunosuppression with gallium nitrate.

4 of 12 patients who failed to respond to the gallium nitrate/5-FU combination responded to M-VAC as s

5 Dose-intense M-VAC is superior to gallium nitrate/5-FU in poor-risk patients (P < .0001).

6 ent in patients who failed to respond to the gallium nitrate/5-FU regimen was also performed.

7 [CI], 1.4% to 36.4%) had a major response to gallium nitrate/5-FU.

8 llograft recipients treated transiently with gallium nitrate accept their grafts for >90 days and fai

9 Thermal decomposition of zinc stearate and gallium nitrate after hot injection of the precursors in

10 Median survival for the gallium nitrate and 5-FU arm was 19 versus 17 months for

11 Gallium nitrate and 5-FU were each administered by conti

12 sed with either GK1.5 monoclonal antibody or gallium nitrate and monitored for donor-reactive delayed

13 ine of the basic and clinical information on gallium nitrate as an antineoplastic agent.

14 Gallium nitrate blocked acute rejection of cardiac allog

15 However, pharmaceutical production of gallium nitrate ceased during the late 1990s, bringing s

16 A phase II randomized trial of gallium nitrate/fluorouracil (5-FU) versus dose-intense

17 s have recently been conducted to reevaluate gallium nitrate for the treatment of lymphoma.

18 eatment of cardiac allograft recipients with gallium nitrate (GN) results in indefinite graft surviva

19 Gallium nitrate (GN) was evaluated for its ability to in

20 t with anti-CD4 monoclonal antibody (mAb) or gallium nitrate (GN) was used to induce acceptance of he

21 allografts and immunosuppressed either with gallium nitrate (GN), or the anti-CD4 monoclonal antibod

22 om mice treated with anti-CD4 Mab (GK1.5) or gallium nitrate (GN).

23 lthough early clinical trials indicated that gallium nitrate had activity against lymphoma and bladde

24 Gallium nitrate has demonstrated activity against lympho

25 Gallium nitrate has recently become commercially availab

26 The mechanism of drug resistance to gallium nitrate is not known.

27 An important property of gallium nitrate is that it is not myelosuppressive and i

28 Simple gallium salts such as gallium nitrate, maltolate, and simple gallium sideropho

29 ents were treated with the immunosuppressant gallium nitrate to promote graft survival.

30 ts with anti-CD4 monoclonal antibody or with gallium nitrate to promote long-term (>60 days) allograf

31 monoclonal antibody-treated mice and 80% of gallium nitrate-treated mice.

32 raft expression of chemokines in hearts from gallium nitrate-treated recipients indicated low levels

33 pproximately 50% of GK1.5-treated and 97% of gallium nitrate-treated transplant recipients.

34 Gallium nitrate treatment could not block acute rejectio

35 when either anti-CD4 monoclonal antibody or gallium nitrate was used for antirejection therapy, (2)

36 lografts, treated with the immunosuppressant gallium nitrate, were explanted at 30, 60, and 90 days a

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。